Shares of TransEnterix (NYSEMKT: TRXC), a medical device company marketing the Senhance robot-assisted surgical system, are plunging again in response to a dismal second-quarter earnings report. Investors disturbed by a lack of new system sales drove the stock 21.7% lower on Thursday. In 2018 Transenterix sold an encouraging 15 Senhance robots.
Full Answer
Why is transenterix stock plunging again?
Apr 14, 2022 · In the past three months, TransEnterix insiders have not sold or bought any company stock. Only 3.10% of the stock of TransEnterix is held by insiders. Only 8.22% of the stock of TransEnterix is held by institutions. Earnings for TransEnterix are expected to grow in the coming year, from ($0.74) to ($0.52) per share.
What is the ticker symbol for transenterix?
Aug 08, 2019 · What happened Shares of TransEnterix (NYSEMKT: TRXC), a medical device company marketing the Senhance robot-assisted surgical system, are plunging again in response to a dismal second-quarter...
Will transenterix's (TRX) earnings grow in the coming year?
Jan 04, 2018 · 10 stocks we like better than TransEnterix When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley ...
What does transenterix do?
Jul 08, 2019 · Shares of TransEnterix (NYSEMKT: TRXC) lost a staggering 39.8% of their value over the first half of 2019, according to data from S&P Global Market Intelligence. What spooked investors? The robotic...
What happened to TransEnterix inc?
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will change its corporate name to Asensus Surgical, Inc.Feb 23, 2021
Is TransEnterix a good buy?
TransEnterix currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.Jan 25, 2021
Why TRXC change name?
However, if you do a Google search for TRXC stock, you may come across some strange results. That's because Transenterix changed its name recently to Asensus Surgical (NYSEAMERICAN:ASXC), reflecting management's decision to focus on the company's Senhance Surgical System.Mar 23, 2021
What happened to TRXC stock?
TRXC stock will begin trading under the new name and ticker ASXC on March 5, 2021. The company said, “the name change [to Asensus Surgical] reflects the company's broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics.”Feb 23, 2021
What is TRXC stock price?
4.08Key Turning Points52-Week High6.95Last Price4.08Fibonacci 50%3.62Fibonacci 38.2%2.8352-Week Low0.281 more row•Mar 4, 2021
What is Tronclassic?
TRONCLASSIC (TRXC) is a cryptocurrency and operates on the Ethereum platform. TRONCLASSIC has a current supply of 1,000,000,000,000 with 0 in circulation.
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) issued its quarterly earnings results on Thursday, November, 5th. The medical instruments supplier reported...
Who are TransEnterix's key executives?
TransEnterix's management team includes the following people: Mr. Todd M. Pope , CEO, Pres & Director (Age 53) Mr. Joseph P. Slattery , Exec. V...
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Utah Medical Products (UTMD) , Accuray (ARAY) , Apollo Endosurgery (APEN) , Apyx Medica...
What other stocks do shareholders of TransEnterix own?
Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals...
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $0.63.
How much money does TransEnterix make?
TransEnterix has a market capitalization of $90.08 million and generates $8.53 million in revenue each year. The medical instruments supplier earns...
What is TransEnterix's official website?
The official website for TransEnterix is www.transenterix.com .
When will Transenterix run out of cash?
TransEnterix thinks its cash and short term assets will run out in mid-2020, which means it has just six months to convince investors the Senhance launch isn't doomed. If it can't, raising significant sums through another equity offering will be nearly impossible.
How much did Transenterix spend on sales?
Transenterix spent $15.5 million on sales and marketing during the first half of 2019 and recorded just $5.8 million in sales. Sadly, the cost of sales was a little higher than revenue, which left nothing to pay for operating expenses that soared to $43.8 million in the first half.
What happened
Shares of TransEnterix (NYSEMKT: TRXC) , a commercial-stage robotic-surgery company, fell 17.5% in December according to data from S&P Global Market Intelligence . The decline has this Fool scratching his head because the only news out of the company during the month was positive.
So what
Investors learned mid-month that TrasnEnterix had sold its SurgiBot assets to a Chinese-based medical-equipment provider. The company is slated to receive at least $29 million from the transaction as a series of payments.
Now what
Short-term price movements aside, this company's fate still hinges on a successful launch of the Senhance System. While the company did record its first U.S. sale already, it's still far too early to draw any real conclusions about the market's reaction to the device.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
An increase in robotic surgery system sales failed to offset concerns over the company's net loss
Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn. Follow @ebcapital
What happened
After reporting a second-quarter 2018 loss and sales that were about in line with its preliminary guidance last month, TransEnterix ( NYSEMKT:ASXC) shares fell 11.7% on Tuesday.
So what
In July, TransEnterix reported preliminary second-quarter revenue of between $6 million and $6.3 million, and today it announced revenue was actually $6.4 million, up 304% from last year.
Now what
The tiny upstart is trying to break into a market that's dominated by Intuitive Surgical, and frankly, the one sale in the U.S. last quarter offers little conviction that it's making headway. For comparison, Intuitive Surgical's da Vinci robots are installed at over 4,000 locations worldwide, and it shipped 220 da Vinci systems in Q2 2018 alone.